Adial Pharmaceuticals, Inc. (Adial) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $6.5 million, with research and development expenses amounting to $454,000 and general and administrative expenses totaling $1.39 million. The loss from operations was $1.85 million, with additional losses from equity method investment and other expenses, including a significant inducement expense of $4.46 million related to warrant exercises. Despite these losses, Adial saw an increase in cash and cash equivalents due to financing activities, primarily from the exercise of warrants. The company's business development efforts included the sale of its subsidiary Purnovate's assets to Adovate LLC, resulting in Adial holding a 19.9% equity stake in Adovate. Looking forward, Adial plans to continue the development of its lead product candidate, AD04, for the treatment of alcohol use disorder, with commercialization not expected until 2026 or later. The company acknowledges the need for additional funding to support its operations and development plans, as current cash reserves are projected to fund operations only into the first quarter of 2025.

Adial Pharmaceuticals, Inc. (Adial) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $6.5 million, with research and development expenses amounting to $454,000 and general and administrative expenses totaling $1.39 million. The loss from operations was $1.85 million, with additional losses from equity method investment and other expenses, including a significant inducement expense of $4.46 million related to warrant exercises. Despite these losses, Adial saw an increase in cash and cash equivalents due to financing activities, primarily from the exercise of warrants. The company's business development efforts included the sale of its subsidiary Purnovate's assets to Adovate LLC, resulting in Adial holding a 19.9% equity stake in Adovate. Looking forward, Adial plans to continue the development of its lead product candidate, AD04, for the treatment of alcohol use disorder, with commercialization not expected until 2026 or later. The company acknowledges the need for additional funding to support its operations and development plans, as current cash reserves are projected to fund operations only into the first quarter of 2025.